Icotinib hydrochloride enhances chemo- and radiosensitivity by inhibiting EGFR signaling and attenuating RAD51 expression and function in Hela S3 cells

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• VaccarellaSLortet-TieulentJPlummerMFranceschiSBrayFWorldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factorsEur J Cancer201349153262327323751569
   PubMed Web of Science ®Google Scholar
• LongHJ3rdBundyBNGrendysECJrGynecologic Oncology Group StudyRandomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group StudyJ Clin Oncol200523214626463315911865
   PubMed Web of Science ®Google Scholar
• FeatherstoneCJacksonSPDNA double-strand break repairCurr Biol1999920R759R76110531043
   PubMed Web of Science ®Google Scholar
• DasariSTchounwouPBCisplatin in cancer therapy: molecular mechanisms of actionEur J Pharmacol201474036437825058905
   PubMed Web of Science ®Google Scholar
• BassingCHAltFWThe cellular response to general and programmed DNA double strand breaksDNA Repair200438–978179615279764
   PubMed Web of Science ®Google Scholar
• CromieGAConnellyJCLeachDRRecombination at double-strand breaks and DNA ends: conserved mechanisms from phage to humansMol Cell2001861163117411779493
   PubMed Web of Science ®Google Scholar
• GoldsteinMKastanMBThe DNA damage response: implications for tumor responses to radiation and chemotherapyAnnu Rev Med20156612914325423595
   PubMed Web of Science ®Google Scholar
• RothkammKKrugerIThompsonLHLobrichMPathways of DNA double-strand break repair during the mammalian cell cycleMol Cell Biol200323165706571512897142
   PubMed Web of Science ®Google Scholar
• San FilippoJSungPKleinHMechanism of eukaryotic homologous recombinationAnnu Rev Biochem20087722925718275380
   PubMed Web of Science ®Google Scholar
• MaackeHOpitzSJostKOver-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancerInt J Cancer200088690791311093813
   PubMed Web of Science ®Google Scholar
• LiYWangWYXiaoJHOverexpression of Rad51 predicts poor prognosis in colorectal cancer: our experience with 54 patientsPLoS One2017121e016786828099437
   PubMed Web of Science ®Google Scholar
• ChenQCaiDLiMWuXThe homologous recombination protein RAD51 is a promising therapeutic target for cervical carcinomaOncol Rep201738276777428627709
   PubMed Web of Science ®Google Scholar
• MasonJMLoganHLBudkeBThe RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumorsCancer Res201474133546355524753542
   PubMed Web of Science ®Google Scholar
• KleinHLThe consequences of Rad51 overexpression for normal and tumor cellsDNA Repair20087568669318243065
   PubMed Web of Science ®Google Scholar
• NormannoNDe LucaABiancoCEpidermal growth factor receptor (EGFR) signaling in cancerGene2006366121616377102
   PubMed Web of Science ®Google Scholar
• HerbstRSReview of epidermal growth factor receptor biologyInt J Radiat Oncol Biol Phys2004592 suppl2126
   PubMed Web of Science ®Google Scholar
• KriegsMKasten-PisulaURieckmannTThe epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joiningDNA Repair20109888989720615764
   PubMed Web of Science ®Google Scholar
• LiccardiGHartleyJAHochhauserDEGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatmentCancer Res20117131103111421266349
   PubMed Web of Science ®Google Scholar
• MorganMAParselsLAKollarLENormolleDPMaybaumJLawrenceTSThe combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancerClin Cancer Res200814165142514918698032
   PubMed Web of Science ®Google Scholar
• WelshJWKomakiRAminiAPhase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancerJ Clin Oncol201331789590223341526
   PubMed Web of Science ®Google Scholar
• GoncalvesAFabbroMLhommeCA phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancerGynecol Oncol20081081424617980406
   PubMed Web of Science ®Google Scholar
• Nogueira-RodriguesAMoralezGGrazziotinRPhase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancerCancer201412081187119324615735
   PubMed Web of Science ®Google Scholar
• SantinADSillMWMcMeekinDSPhase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyGynecol Oncol2011122349550021684583
   PubMed Web of Science ®Google Scholar
• TanFShenXWangDIcotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studiesLung Cancer201276217718222112293
   PubMed Web of Science ®Google Scholar
• ZhaoQShentuJXuNPhase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumorsLung Cancer201173219520221144613
   PubMed Web of Science ®Google Scholar
• CamidgeDRIcotinib: kick-starting the Chinese anticancer drug industryLancet Oncol2013141091391423948350
   PubMed Web of Science ®Google Scholar
• ShiYZhangLLiuXIcotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trialLancet Oncol2013141095396123948351
   PubMed Web of Science ®Google Scholar
• SungPKleinHMechanism of homologous recombination: mediators and helicases take on regulatory functionsNat Rev Mol Cell Biol200671073975016926856
   PubMed Web of Science ®Google Scholar
• KersemaekersAMFleurenGJKenterGGOncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosisClin Cancer Res19995357758610100709
   PubMed Web of Science ®Google Scholar
• LiQTangYChengXJiJZhangJZhouXEGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervixInt J Clin Exp Pathol20147273374124551297
   PubMed Web of Science ®Google Scholar
• NoordhuisMGEijsinkJJTen HoorKAExpression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancerClin Cancer Res200915237389739719920104
   PubMed Web of Science ®Google Scholar
• BaguleyBCMarshallESHoldawayKMRewcastleGWDennyWAInhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinasesEur J Cancer1998347108610909849459
   PubMed Web of Science ®Google Scholar
• DaiQLingYHLiaMEnhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell linesClin Cancer Res20051141572157815746062
   PubMed Web of Science ®Google Scholar
• de la RochefordiereAKamalMFloquetAPIK3CA pathway mutations predictive of poor response following standard radiochemotherapy ± cetuximab in cervical cancer patientsClin Cancer Res201521112530253725724520
   PubMed Web of Science ®Google Scholar
• Nogueira-RodriguesAdo CarmoCCViegasCPhase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancerClin Cancer Res200814196324632918829516
   PubMed Web of Science ®Google Scholar
• UllrichASchlessingerJSignal transduction by receptors with tyrosine kinase activityCell19906122032122158859
   PubMed Web of Science ®Google Scholar
• ChapmanJRTaylorMRBoultonSJPlaying the end game: DNA double-strand break repair pathway choiceMol Cell201247449751022920291
   PubMed Web of Science ®Google Scholar
• NowosielskaAMarinusMGCisplatin induces DNA double-strand break formation in Escherichia coli dam mutantsDNA Repair20054777378115925551
   PubMed Web of Science ®Google Scholar
• BasuAKrishnamurthySCellular responses to Cisplatin-induced DNA damageJ Nucleic Acids2010201016
   Google Scholar
• RassEChandramoulyGZhaSAltFWXieAAtaxia telangiectasia mutated (ATM) is dispensable for endonuclease I-SceI-induced homologous recombination in mouse embryonic stem cellsJ Biol Chem2013288107086709523355489
   PubMed Web of Science ®Google Scholar
• MahLJOrlowskiCVerverisKEvaluation of the efficacy of radiation-modifying compounds using gammaH2AX as a molecular marker of DNA double-strand breaksGenome Integr201121321261999
   PubMedGoogle Scholar
• MahLJEl-OstaAKaragiannisTCgammaH2AX: a sensitive molecular marker of DNA damage and repairLeukemia201024467968620130602
   PubMed Web of Science ®Google Scholar
• RodemannHPDittmannKToulanyMRadiation-induced EGFR-signaling and control of DNA-damage repairInt J Radiat Biol20078311–1278179118058366
   PubMed Web of Science ®Google Scholar
• HsuSCMillerSAWangYHungMCNuclear EGFR is required for cisplatin resistance and DNA repairAm J Transl Res20091324925819956435
   PubMed Web of Science ®Google Scholar
• DittmannKMayerCRodemannHPInhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activityRadiother Oncol200576215716116024112
   PubMed Web of Science ®Google Scholar
• FriedmannBCaplinMHartleyJAHochhauserDModulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839)Clin Cancer Res200410196476648615475435
   PubMed Web of Science ®Google Scholar
• LiuHYangWGaoHNimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repairOnco Targets Ther2015850951825750543
   PubMed Web of Science ®Google Scholar
• ChenRSJhanJYSuYJEmodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivationExp Cell Res2009315152658267219505457
   PubMed Web of Science ®Google Scholar